Novartis AG
USE OF IL-1BETA BINDING ANTIBODIES

Abstract:

Use of an IL-I.beta. binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment of cancer with at least partial inflammatory basis, e.g., CML.